AAN 2009: Incidence of PML with Natalizumab in MS Lower Than Previously Thought
 

AAN 2009: Incidence of PML with Natalizumab in MS Lower Than Previously Thought

http://www.medscape.com/viewarticle/702373

Viewing the article requires registration (which is free). Let me know if you'd like me to cut and paste the article in this thread.

Could you post it here, Chris?

According to any calculation, PML is lower than the worst case scenario predicted . . . but I am interested in what the article says anyway.

Thanks
Cherie

No Cherie, he can't.
No full articles are to posted. Medscape is clearly marked COPYRIGHT.


All material on this website is protected by copyright, Copyright © 1994-2009 by Medscape. This website also contains material copyrighted by 3rd parties

Cherie,

The article is too long to PM without cutting it down and it should be read in its entirety. It's easy to register with Medscape to view the entire article. It's the first medical article I've seen where Biogen has quoted PML risk numbers. I'm sure it won't stop the discussion of PML risk but at least its something public from Biogen.

Chris

Chris, you can send more than one PM. Just break up the article.

Excellent suggestion! Clearly, obvious solutions are not obvious to me at this time. Thankfully today's almost over!

Maybe you need to eat some of those noodles...carbs for the brain. :p

http://thm-a04.yimg.com/image/47540db513139364

Do you need a fork and sponn too? :D

By the time I got back here, it was posted on another forum already . . . so thanks anyway, Chris.

That was ridiculous, and we both know why . . . but whatever.:rolleyes:

Cherie

The article presents all the commercial usage experience PML data in a relatively clinical fashion. What's ridiculous about that? I don't necessarily agree with all the conclusions (i.e. PML cases are random with no connections/similarities) but the data presented is of value.